Literature DB >> 10922223

The cost of juvenile-onset recurrent respiratory papillomatosis.

D Bishai1, H Kashima, K Shah.   

Abstract

OBJECTIVE: To assess the medical costs and the number of quality-adjusted life years lost owing to juvenile-onset recurrent respiratory papillomatosis (JORRP).
DESIGN: We examined hospital and physician charges for JORRP surgical procedures in Maryland in 1994 adjusting for inflation and the cost-charge ratio. Centers for Disease Control and Prevention data on treatment intensity for JORRP were augmented with a review of treatment records for 18 patients with JORRP. Sensitivity analyses were performed. To illustrate the application of our cost estimates, we compare the costs of JORRP to the costs of the surgical procedures that would be necessary to prevent it.
RESULTS: We find that the present value at birth of the cost of a single case of JORRP is $201,724 (range, $61,822-$474,334). The annual cost for a single case of JORRP is $57,996 (range, $32,407-$94,114). The annual cost of JORRP in the United States is between $40 million and $123 million depending on the prevalence. Cesarean section (CS) for women with condyloma has been suggested as a potential strategy to prevent JORRP, but its efficacy remains to be determined. Our results suggest that if only 1% of the CSs actually prevented JORRP, this strategy would be a cost-effective means to prevent JORRP.
CONCLUSIONS: Studies to reduce the uncertainty surrounding the efficacy of CS and the effect of both CS and JORRP on families need to precede consideration of a policy of CS for women with clinically evident genital condyloma. Patients should be kept thoroughly informed about the role of CS for the prevention of JORRP and the nature of the remaining uncertainties.

Entities:  

Mesh:

Year:  2000        PMID: 10922223     DOI: 10.1001/archotol.126.8.935

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  20 in total

1.  Office-based Management of Recurrent Respiratory Papilloma.

Authors:  Kevin M Motz; Alexander T Hillel
Journal:  Curr Otorhinolaryngol Rep       Date:  2016-03-31

Review 2.  Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Recurrent respiratory papillomatosis: an overview.

Authors:  Qingliang Xue; Haitao Wang; Jianxin Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-28       Impact factor: 3.267

Review 4.  The economic burden of noncervical human papillomavirus disease in the United States.

Authors:  Delphine Hu; Sue Goldie
Journal:  Am J Obstet Gynecol       Date:  2008-05       Impact factor: 8.661

5.  Multicenter initiative seeking critical genes in respiratory papillomatosis.

Authors:  Farrel J Buchinsky; Craig S Derkay; Suzanne M Leal; Joseph Donfack; Garth D Ehrlich; J Christopher Post
Journal:  Laryngoscope       Date:  2004-02       Impact factor: 3.325

6.  Suppression of respiratory papillomatosis with malignant transformation by erlotinib in a kidney transplant recipient.

Authors:  Zhonglin Hao; Thomas Dillard; Paul Biddinger; Vijay Patel
Journal:  BMJ Case Rep       Date:  2013-08-28

7.  Health and economic implications of HPV vaccination in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

8.  HLA class II polymorphisms and susceptibility to recurrent respiratory papillomatosis.

Authors:  Colin M Gelder; O Martin Williams; Keith W Hart; Siôn Wall; Gareth Williams; Duncan Ingrams; Peter Bull; Mike Bunce; Ken Welsh; Sara E F Marshall; Leszek Borysiewicz
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States.

Authors:  Jane J Kim; Sue J Goldie
Journal:  BMJ       Date:  2009-10-08

10.  Economic burden of human papillomavirus-related diseases in Italy.

Authors:  Gianluca Baio; Alessandro Capone; Andrea Marcellusi; Francesco Saverio Mennini; Giampiero Favato
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.